Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

100.0%

2 terminated/withdrawn out of 2 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT00209599Phase 2Terminated

A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy

Role: collaborator

NCT00209586Phase 3Terminated

A Study of AQUAVAN® Injection for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy

Role: collaborator

All 2 trials loaded